ced-3 encodes a cysteine protease (caspase) that acts as the central executioner of programmed cell death (apoptosis) in C. elegans. As the founding member of the apoptosis pathway first defined in this organism, ced-3 loss-of-function mutants are viable yet block the vast majority of somatic cell deaths, making them an indispensable tool for studying cell death mechanisms, corpse clearance, and synthetic lethal interactions.
CD BioSciences has established a mature, optimized genome-editing platform for C. elegans. Leveraging CRISPR/Cas9 and the broadly used co-CRISPR selection markers, we design and deliver custom ced-3 alleles — including targeted knockouts, fluorescent or epitope tag knockins, and site-specific point mutations — with full genotype verification and a clear reporting package.
| Gene symbol | ced-3 (cell death abnormal-3) |
|---|---|
| Protein product | CED-3 — executioner/inflammatory-type cysteine protease (caspase) |
| Mammalian homolog | CASP3 / CASP7 / CASP9 (apoptotic caspases) |
| Biological role | Central executioner of somatic apoptosis; activated downstream of EGL-1 → CED-9 → CED-4 |
| Loss-of-function phenotype | Blocks ~109 of 131 programmed somatic cell deaths; animals viable with persistent extra cells |
| Why edit it | Foundational model for apoptosis, cell-death regulation, corpse engulfment, and human caspase-related disease |
| Recommended background | N2 (wild type); can be crossed into co-CRISPR selection or fluorescent reporter backgrounds |
A summary of the conserved apoptosis pathway in C. elegans: egl-1 (BH3-only) antagonizes ced-9 (anti-apoptotic), releasing ced-4 (Apaf-1-like) to activate ced-3, which cleaves cellular substrates to execute death. Editing ced-3 alone is typically sufficient to phenocopy the cell-death-defective state.
gRNA-guided Cas9 cutting with NHEJ repair to introduce frameshift indels, generating premature stop codons and null/strong-loss-of-function ced-3 alleles.
Homology-directed repair (HDR) inserts GFP/HA/FLAG or other tags at the ced-3 locus for endogenous expression and subcellular localization studies.
Introduce specific amino-acid substitutions (e.g., catalytic-site mutations) to separate catalytic from scaffolding functions of CED-3.
Build tissue-specific or inducible configurations and caspase-activity reporters for spatiotemporal analysis of apoptosis.
Define target (knockout / knockin / point mutation), select gRNA(s) and HDR template, confirm against the latest genome build.
Design, validate, and synthesize high-specificity guide RNAs targeting the ced-3 locus.
Build Cas9/gRNA delivery construct and, for knockin, the homology-arm repair template.
Perform gonadal microinjection of N2 animals with CRISPR components and co-CRISPR selection markers.
PCR, Sanger/sequencing, and phenotype confirmation to isolate edited animals and verify alleles.
Provide homozygous/balanced ced-3 strains plus a full genotype and methods report.
Standard knockout projects deliver a frameshift indel allele predicted to produce a premature stop and a loss-of-function phenotype. We confirm the edit by sequencing and, where relevant, by the characteristic cell-death-defective phenotype.
Yes. Using HDR with a designed repair template, we can insert GFP, HA, or FLAG tags at the C- or N-terminus while preserving endogenous promoter and regulation.
Timelines vary with editing type and validation needs, but our optimized pipeline and co-CRISPR selection typically shorten turnaround versus conventional approaches. Contact us with your design for a project-specific estimate.
We primarily edit the N2 background but can outcross edited alleles into fluorescent reporter or other requested backgrounds upon request.
CD BioSciences is committed to convenient, efficient, and cost-effective C. elegans model customization. Tell us your target design — knockout, knockin, tagging, or point mutation — and our scientists will respond with a tailored plan and quote.
Contact UsReference
1. Kim H. M., Colaiácovo M. P. CRISPR-Cas9-guided genome engineering in C. elegans. Current Protocols in Molecular Biology, 2016, 115(1): 31.7.1–31.7.18.
For research use only.
Copyright © 2026 CD BioSciences. All rights reserved.